Information Provided By:
Fly News Breaks for August 21, 2015
PTN
Aug 21, 2015 | 09:22 EDT
Noble said Valeant's (VRX) acquisition of Sprout for $1B underscores that Palatin is undervalued and noted its drug candidate bremelanotide is an on-demand treatment, unlike flibanserin taken daily, and has a distinct MoA and is devoid of the safety risks associated with flibanserin. The firm rates shares a Buy with a $4 price target.
News For PTN From the Last 2 Days
There are no results for your query PTN